Prior history of allergic reactions to G-CSF
Patients who have exhibited allergic reactions to a similar structural compound or to a formulation component of CX-4945.
History of documented allergic reactions or acute hypersensitivity reaction attributed to antibody treatments;
Subjects who have exhibited allergic reactions to tipifarnib, or structural compounds similar to tipifarnib or to its excipients.
Patient has a history of allergic reactions attributed to perillyl alcohol.
History of allergic reactions attributed to components of the formulated product
History of allergic reactions to any component of the IMP.
History of allergic reactions attributed to cyclophosphamide or alemtuzumab
EXCLUSION - INFUSION: History of allergic reactions attributed to nivolumab or any other checkpoint inhibitors
History of allergic reactions attributed to oral vancomycin or oral polymyxin B
A history of serious allergic reactions, which in the opinion of the investigator pose an increased risk of serious infusion reactions.
History of allergic reactions to pralatrexate or romidepsin
Hypersensitivity (history of allergic reactions) to
History of allergic reactions or sensitivity to pyrimethamine
History of allergic reactions to either azacitidine or ascorbic acid
Patients with history of allergic or toxic reactions attributed to cytarabine or a history of allergic reactions to components of the formulated product
Patients with history of allergic or toxic reactions attributed to anthracyclines or a history of allergic reactions to components of the formulated product
History of allergic reactions attributed to monoclonal antibodies (grade >= 3)
History of allergic reactions to carboplatin or paclitaxel
History of allergic reactions to SGI-110 or decitabine
History of, or suspected allergic reactions to durvalumab, pralatrexate, oral 5-azacitidine, or romidepsin or any of their excipients
History of severe allergic reactions (as determined by treating physician) attributed to the drugs being used in the study
History of allergic reactions to products containing mouse and bovine protein antibodies.
Patients with a history of allergic reactions attributed to docetaxel or paclitaxel are ineligible
Allergic reactions or acute hypersensitivity reaction attributed to antibody treatments
Any known allergy or allergic reactions to Captisol
History of allergic reactions to TGR-1202 or carfilzomib
History of uncontrollable allergic reactions to bevacizumab or ascorbic acid
Patients who have known allergic reactions to paclitaxel or IV contrast dye despite standard prophylaxis
History of allergic reactions attributed to doxorubicin or Doxil.
History of uncontrollable allergic reactions to vitamin D
Documented allergic reactions or similar to antibody treatments
No life-threatening allergy to bakerâ€™s yeast or other components of the vaccines; no history of allergic reactions to the antibiotics neomycin, streptomycin or polymyxin B
Propensity to allergic reactions defined as a history of allergic reaction to more than one medication
History of allergic reactions attributed to Flagyl (metronidazole), which has a chemical structure similar to EF5
Have any known allergic reactions to any of the drugs or liposomal components or intravenous imaging agents that prohibit the ability to complete the imaging requirements.
History of allergic reactions or hypersensitivity to the study drugs (hydroxychloroquine, gemcitabine, Abraxane)
History of prior allergic reactions attributed to compounds of CT/MRI contrast that cannot be managed with appropriate pre-medication prophylaxis and thereby preclude use of baseline/ follow-up or radiation planning imaging
History of allergic reactions to recombinant IL-2
History of allergic reactions or intolerance to any of the required agents on the study
History of allergic reactions attributed to metformin or other biguinides
Patients who have known allergic reactions to IV contrast dye despite standard prophylaxis
History of allergic reactions to study compounds or excepients Additional exclusion criteria Part A: Patients with clinically active brain metastases and prior exposure to AZD9150, AZD5069, MEDI4736, or any other anti PD (L)1 antibody.
Known sensitivity or allergic reactions to acyclovir or valacyclovir
History of allergic reactions to mouse antigens
Patients who have exhibited allergic reactions to a similar structural compound or to a formulation component.
History of allergic reactions to any components of the treatments
History of allergic reactions to cetuximab.
Has history of asthma, or other allergic-type reactions after taking aspirin or other NSAIDs
History of severe allergic reactions attributed to any vaccine therapy for the prevention of infectious diseases
Patients who have exhibited allergic reactions to compounds structurally similar to APTO-253 HCI
History of severe allergic reactions attributed to any vaccine therapy for the prevention of infectious diseases
History of allergic or idiosyncratic/hypersensitivity reactions to 8-methoxypsoralen/psoralen compounds
History of allergic reactions or intolerance to any of the required agents on the study
Known history of allergic reactions to paclitaxel
History of allergic reactions attributed to riluzole or sorafenib
Patients with a history of allergic reactions to carboplatin and/or paclitaxel or chemically similar compounds; patients with allergic (hypersensitivity) reactions to these chemotherapeutic agents are NOT excluded IF they were successfully retreated following a desensitization program or protocol
Known allergy(ies) to any component of CMB305, atezolizumab, or severe allergic reactions to monoclonal antibodies, fusion proteins, or CHO cell products.
History of allergic reactions to carboplatin, platinum containing compounds or mannitol and/or hypersensitivity to PLD or to any of the excipients
History of allergic reactions to Cremophor EL, paclitaxel or its components
Patients with prior grade 3 allergic or infusion reactions to docetaxel, cisplatin or cetuximab are not eligible; a history of well tolerated infusion reactions is NOT an exclusion
History of clinically significant allergic reactions or atopic disease that may pose an increased risk of severe CDX-0158 IRRs.
History of serious allergic reactions including anaphylaxis and toxic epidermal necrolysis
Patients with a history of grade 4 allergic reactions to anti-GD2 antibodies or reactions that required discontinuation of the anti-GD2 therapy are not eligible
History of allergic reactions to imiquimod or its excipients
History of allergic reactions attributed to therapeutic antibodies; Note: patients with reactions to chimeric antibodies may be permitted on a case by case basis with approval by study chair by contacting the data manager
Prior allergic reactions attributed to other monoclonal antibodies
Patients with a history of allergic reactions attributed to eribulin or irinotecan
History of uncontrollable allergic reactions to temozolomide or ascorbic acid or to antiemetics appropriate for administration in conjunction with protocol-directed chemotherapy
Any previous treatment with LDE225 or allergic reactions to excipients of LDE225
History of allergic reactions attributed to thalidomide or lenalidomide
History of allergic reactions to oral 5-azacitidine or romidepsin
History of allergic reactions attributed to fluoropyrimidine (e.g., capecitabine, fluorouracil, fluorodeoxyuridine) or tetrahydrouridine
History of serious allergic reactions to pegfilgrastim or filgrastim
Experienced allergic reactions to monoclonal antibodies or other therapeutic proteins.
History of allergic reactions to bacterially-produced proteins
History of allergic reactions to medicines containing polyoxyethylated castor oil that are not controlled with premedications
History of allergic reactions attributed to trastuzumab (cohorts 1, 3) that were not treatable/preventable with pre-medications or desensitization protocols
Acute allergic disorders or a history of severe allergic reactions
History of anaphylaxis or serious allergic reactions to previous administration of any of the vaccines
Patients who have known allergic reactions to paclitaxel or IV contrast dye despite standard prophylaxis
History of allergic reactions attributed to fluoropyrimidines (e.g., capecitabine, fluorouracil, fluorodeoxyuridine) or tetrahydrouridine
Patients with a history of serious allergic reactions
History of allergic reactions to monoclonal antibody therapy (or excipients in the formulation)
Patients with a history of allergic reactions attributed to compounds of similar composition to dolastatin or auristatin (e.g. Auristatin PHE, Auristatin PE, and symplostatin)
History of allergic reactions attributed to components of the formulated product(s)
Generalized dermatologic conditions (such as allergic reactions, infection, edema, or scarring) that will not allow for study drug administration at a site of normal skin or evaluation of localized adverse events
History of allergic reactions to anilinoquinazolins like gefitinib, erlotinib, or BIBW2992
History of allergic or toxic reactions attributed to cytarabine (Part 2) or history of allergic reactions to components of the formulated product
Subjects with a history of allergic reactions to lactose.
Contraindication to steroid use or history of allergic reactions attributable to the study compounds
History of allergic reactions to bacterially-produced proteins
History of allergic reactions to the study drugs, their analogs or any component of the products
History of reactions to liposomal drug formulations other than PLD should be evaluated individually and if their reactions were felt to have been due to the encapsulated agent, rather than the liposomal component itself they should be excluded at the discretion of the investigators
The patient has a history of allergic reactions likely to be exacerbated by any component of the study investigational product.
History of allergic reactions to quinalones or chloroquine.
Patients with history of life threatening allergic reactions to food or drugs
History of allergic reactions attributed to compounds chemically related to lapatinib (quinazolines), capecitabine, fluorouracil or any excipients;
The patient has a history of allergic reactions likely to be exacerbated by any component of the study investigational product.
History of allergic reactions attributed to:\r\n* Study agent or its metabolites\r\n* Iodinated contrast media
History of hypersensitivity reactions attributed to simvastatin
Previous allergic reactions to dexamethasone.
History of allergic reactions to whey or milk proteins
Must not have a contraindication for using lidocaine: e.g. no history of allergic reactions to lidocaine
History of allergic reactions to whey protein
Subjects with history of allergic reactions to ketamine
History of allergic or other adverse reactions to minocycline
History of allergic or other adverse reactions to tetracycline
A history of allergic reactions attributed to either Monocryl suture or stainless steel staples
Previous allergic reactions to dexamethasone
Prior significant allergic reactions to drugs containing Cremophor, such as cyclosporine, or vitamin K are not eligible; a significant reaction may be defined as, but is not limited to, the description of grade  = 3 allergic reactions using the Common Toxicity Criteria (CTC)
Evidence or history of clinically significant allergic reactions to varenicline
History of allergic reactions attributed to naproxen
History of allergic reactions or hypersensitivity to compounds similar to trastuzumab and/or letrozole
Have a history of allergic reactions to metformin or similar drugs
Evidence or history of clinically significant allergic reactions to varenicline
History of allergic reactions or hypersensitivity to ketamine
There will be no exclusion requirements due to co-morbid disease or incurrent illness\r\n* History of allergic reactions to similar compounds will be obtained and patients with positive history of allergic reactions will be excluded from the study
Since the diagnostic MR examination does not require injection of contrast agent there will be no specific requirements regarding history of allergic reactions
History of allergic reactions to similar compounds will be obtained and patients with positive history of allergic reactions will be excluded from the study
Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals; patients with significant drug or other allergies or autoimmune diseases may be enrolled at the investigatorâ€™s discretion
Known allergic reactions to components of the study product(s)
Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals; patients with significant drug or other allergies or autoimmune diseases may be enrolled at the investigatorâ€™s discretion
Patients with contraindications to the use of intravenous contrast such as allergic type reactions
History of multiple or severe allergic reactions attributed to immunoglobulins or MRI contrast agents
Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals; patients with significant drug or other allergies or autoimmune diseases may be enrolled at the investigator's discretion
Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals; patients with significant drug or other allergies or autoimmune diseases may be enrolled at the Investigatorâ€™s discretion
Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals; patients with significant drug or other allergies or autoimmune diseases may be enrolled at the Investigator's discretion
History of allergic reactions to INCB062079, any of the excipients of INCB062079 or similar compounds.
Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals (patients with significant drug or other allergies or autoimmune diseases may be enrolled at the investigatorâ€™s discretion)
Subjects who have experienced allergic or other adverse reactions in response to intravenous injection of fluorinated radiotracers and other contrast media used in PET/CT
No restrictions on allergic reactions as no imaging agent will be used
History of allergic reactions attributed to ICG or other agents used in the study, including known iodide or seafood allergy
History of allergic reactions attributed to 5 azacitidine
Patients may not have a history of severe allergic reactions to paclitaxel or other drugs formulated in cremaphorÂ® EL
History of hypersensitivity or allergic reactions requiring corticosteroids, epinephrine, and/or hospitalization.
